Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers

1. Has a history or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.

2. Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results, in the opinion of an Investigator.

3. Has had an acute illness (e.g., upper respiratory infection, viral infection) requiring treatment within 14 days prior to Baseline.

4. Has a fever (\>100.5°F) at Screening or Baseline.

5. Has a body mass index (BMI) \>40.0 kg/m2 or \<18.0 kg/m2 at Screening.

6. Has a history of drug or alcohol abuse within 24 months of Screening, as determined by the Investigator.

7. Has or has a history of diabetes mellitus, asthma, or chronic obstructive pulmonary disease.

8. Has a systolic blood pressure \<90 or \>150 mmHg, diastolic blood pressure \<40 or \>95 mmHg, or heart rate \<40 or \>99 bpm at Screening.

9. Has experienced an allergic reaction following previous e-cigarette use or with exposure to any primary components of the e-liquids (nicotine, flavor, benzoic acid, propylene glycol and glycerol).

10. Has a positive urine screen for alcohol or drugs of abuse at Screening or Baseline.

11. If female, the subject is pregnant, has a positive urine pregnancy test at screening, is lactating, or intends to become pregnant during the time period from screening through the end of study.

12. Has used any nicotine-containing product other than closed-system ENDS products (e.g., cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 14 days prior to Baseline.

13. Has used any prescription cessation treatments, including, but not limited to, varenicline (Chantix®) or bupropion (Zyban®) within 3 months prior to Screening.

14. Negative response (i.e., unwilling to use or unable to tolerate; e.g., experiences AEs during the product trial that will prevent the subjects from continuing to use the study products as judged by the Investigator) to any of the JUUL products at Screening.

15. Is a self-reported puffer (i.e., draws aerosol into the mouth and throat but do not inhale).

16. Is planning to quit ENDS product use during the study or postponing (within 30 days of screening) a quit attempt in order to participate in the study.

17. Has participated in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to Screening.

18. Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee of the study site.

19. Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee, shareholder, or is member of the board of directors of JUUL Labs Inc.

20. Has previously taken part in, has been excluded or withdrawn from, or has completed this study.

21. In the opinion of the Investigator, the subject should not participate in this study.

What this study is about